Appendix B

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Proposed Single Technology Appraisal (STA)

Rituximab for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs

Matrix of consultees and commentators

Consultees	**Commentators (no right to submit or appeal)**
Manufacturers/sponsors • Rituximab (Roche Products) Patient/carer groups • Action on Pain • Afiya Trust • Arthritic Association • Arthritis & Musculoskeletal Alliance (ARMA) • Arthritis Care • Black Health Agency • Chinese National Healthy Living Centre • Counsel and Care • Equalities National Council • Leonard Cheshire Disability • Muslim Council of Britain • Muslim Health Network • National Rheumatoid Arthritis Society • Pain Concern • Pain Relief Foundation • Royal Association for Disability & Rehabilitation (RADAR) • South Asian Health Foundation • Specialised Healthcare Alliance Professional groups • British Association for Services to the Elderly • British Geriatrics Society • British Health Professionals in Rheumatology • British Institute of Musculoskeletal Medicine	General • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Commissioning Support Appraisals Service • Department of Health, Social Services and Public Safety for Northern Ireland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • NHS Quality Improvement Scotland • Public Health Wales NHS Trust • Scottish Medicines Consortium Comparator manufacturer(s) • AAH Pharmaceuticals (azathioprine, sulfasalazine, penicillamine) • Abbott Laboratories (adalimumab) • Actavis (azathioprine, sulfasalazine, penicillamine) • Almus Pharmaceuticals (sulfasalazine) • Arrow Generics (azathioprine) • AstraZeneca (chloroquine) • Focus Pharmaceuticals (azathioprine) • Genesis Pharmaceuticals (sulfasalazine) • GlaxoSmithKline (azathioprine) • Kent Pharmaceuticals (azathioprine, sulfasalazine, penicillamine)

Consultees	**Commentators (no right to submit or appeal)**
• British Institute of Radiology • British Orthopaedic Association • British Pain Society • British Society for Rheumatology • British Society of Rehabilitation Medicine • Physiotherapy Pain Association • Primary Care Rheumatology Society • Rheumatoid Arthritis Surgical Society • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine – Intellectual Disabilities Forum • Society and College of Radiographers • United Kingdom Clinical Pharmacy Association <u>Others</u> • Bradford and Airedale Teaching PCT • Department of Health • NHS Hertfordshire • Welsh Assembly Government	• Metwest Pharmaceuticals (sulfasalazine) • Mylan (azathioprine, sulfasalazine, penicillamine) • Novartis (ciclosporin) • Pfizer (sulfasalazine) • Rosemont Pharmaceuticals (sulfasalazine) • Sandoz (azathioprine) • Sanofi Aventis (hydroxychloroquine, leflunomide, sodium aurothiomalate) • Schering-Plough (infliximab, golimumab) • Teva UK (azathioprine, sulfasalazine, penicillamine) • Tillomed Laboratories (azathioprine) • UCB Pharma (certolizumab pegol) • Wyeth Pharmaceuticals (etanercept) <u>Relevant research groups</u> • Arthritis Research Campaign • Chronic Pain Policy Coalition • MRC Clinical Trials Unit • National Institute for Health Research • Policy Research Institute on Ageing and Ethnicity • Research Institute for the Care of Older People <u>Evidence Review Group</u> • West Midlands Health Technology Assessment Collaboration • National Institute for Health Research Health Technology Assessment Programme <u>Associated Guideline Groups</u> • National Clinical Guideline Centre <u>Associated Public Health Groups</u> • None

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement[1], respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

[1] Non manufacturer consultees are invited to submit statements relevant to the group they are representing.